Literature DB >> 18849586

Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.

Kimihiko Oishi1, Hui Zhang, William J Gault, Cindy J Wang, Cheryl C Tan, In-Kyong Kim, Huiwen Ying, Tabassum Rahman, Natalie Pica, Marco Tartaglia, Marek Mlodzik, Bruce D Gelb.   

Abstract

Missense mutations in the PTPN11 gene, which encodes the protein tyrosine phosphatase SHP-2, cause clinically similar but distinctive disorders, LEOPARD (LS) and Noonan (NS) syndromes. The LS is an autosomal dominant disorder with pleomorphic developmental abnormalities including lentigines, cardiac defects, short stature and deafness. Biochemical analyses indicated that LS alleles engender loss-of-function (LOF) effects, while NS mutations result in gain-of-function (GOF). These biochemical findings lead to an enigma that how PTPN11 mutations with opposite effects on function result in disorders that are so similar. To study the developmental effects of the commonest LS PTPN11 alleles (Y279C and T468M), we generated LS transgenic fruitflies using corkscrew (csw), the Drosophila orthologue of PTPN11. Ubiquitous expression of the LS csw mutant alleles resulted in ectopic wing veins and, for the Y279C allele, rough eyes with increased R7 photoreceptor numbers. These were GOF phenotypes mediated by increased RAS/MAPK signaling and requiring the LS mutant's residual phosphatase activity. Our findings provide the first evidence that LS mutant alleles have GOF developmental effects despite reduced phosphatase activity, providing a rationale for how PTPN11 mutations with GOF and LOF produce similar but distinctive syndromes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849586      PMCID: PMC2644650          DOI: 10.1093/hmg/ddn336

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  40 in total

1.  Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.

Authors:  Nadine Hanna; Alexandra Montagner; Wen Hwa Lee; Maria Miteva; Michel Vidal; Michel Vidaud; Béatrice Parfait; Patrick Raynal
Journal:  FEBS Lett       Date:  2006-04-12       Impact factor: 4.124

2.  PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.

Authors:  Maria I Kontaridis; Kenneth D Swanson; Frank S David; David Barford; Benjamin G Neel
Journal:  J Biol Chem       Date:  2005-12-23       Impact factor: 5.157

3.  Identification of genomic regions that interact with a viable allele of the Drosophila protein tyrosine phosphatase corkscrew.

Authors:  L Firth; J Manchester; J A Lorenzen; M Baron; L A Perkins
Journal:  Genetics       Date:  2000-10       Impact factor: 4.562

4.  Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.

Authors:  Heike Keilhack; Frank S David; Malcolm McGregor; Lewis C Cantley; Benjamin G Neel
Journal:  J Biol Chem       Date:  2005-06-29       Impact factor: 5.157

5.  Systematic analysis of the transcriptional switch inducing migration of border cells.

Authors:  Lodovica Borghese; Georgina Fletcher; Juliette Mathieu; Ann Atzberger; William C Eades; Ross L Cagan; Pernille Rørth
Journal:  Dev Cell       Date:  2006-04       Impact factor: 12.270

Review 6.  The MAPK pathway in melanoma.

Authors:  Leslie A Fecher; Ravi K Amaravadi; Keith T Flaherty
Journal:  Curr Opin Oncol       Date:  2008-03       Impact factor: 3.645

Review 7.  Germ-line and somatic PTPN11 mutations in human disease.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Eur J Med Genet       Date:  2005-04-02       Impact factor: 2.708

8.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.

Authors:  Bhaswati Pandit; Anna Sarkozy; Len A Pennacchio; Claudio Carta; Kimihiko Oishi; Simone Martinelli; Edgar A Pogna; Wendy Schackwitz; Anna Ustaszewska; Andrew Landstrom; J Martijn Bos; Steve R Ommen; Giorgia Esposito; Francesca Lepri; Christian Faul; Peter Mundel; Juan P López Siguero; Romano Tenconi; Angelo Selicorni; Cesare Rossi; Laura Mazzanti; Isabella Torrente; Bruno Marino; Maria C Digilio; Giuseppe Zampino; Michael J Ackerman; Bruno Dallapiccola; Marco Tartaglia; Bruce D Gelb
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

9.  Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.

Authors:  Kimihiko Oishi; Konstantin Gaengel; Srinivasan Krishnamoorthy; Kenichi Kamiya; In-Kyong Kim; Huiwen Ying; Ursula Weber; Lizabeth A Perkins; Marco Tartaglia; Marek Mlodzik; Leslie Pick; Bruce D Gelb
Journal:  Hum Mol Genet       Date:  2006-01-06       Impact factor: 6.150

10.  Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.

Authors:  Chris Jopling; Daphne van Geemen; Jeroen den Hertog
Journal:  PLoS Genet       Date:  2007-12       Impact factor: 5.917

View more
  44 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 2.  The neural crest in cardiac congenital anomalies.

Authors:  Anna Keyte; Mary Redmond Hutson
Journal:  Differentiation       Date:  2012-05-15       Impact factor: 3.880

Review 3.  Understanding intellectual disability through RASopathies.

Authors:  Alvaro San Martín; Mario Rafael Pagani
Journal:  J Physiol Paris       Date:  2014-05-21

4.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

5.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

Review 6.  Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Authors:  Zhi-Hong Yu; Zhong-Yin Zhang
Journal:  Chem Rev       Date:  2017-05-25       Impact factor: 60.622

7.  Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Authors:  Zhi-Hong Yu; Jie Xu; Chad D Walls; Lan Chen; Sheng Zhang; Ruoyu Zhang; Li Wu; Lina Wang; Sijiu Liu; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2013-03-01       Impact factor: 5.157

8.  Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome.

Authors:  Xonia Carvajal-Vergara; Ana Sevilla; Sunita L D'Souza; Yen-Sin Ang; Christoph Schaniel; Dung-Fang Lee; Lei Yang; Aaron D Kaplan; Eric D Adler; Roye Rozov; Yongchao Ge; Ninette Cohen; Lisa J Edelmann; Betty Chang; Avinash Waghray; Jie Su; Sherly Pardo; Klaske D Lichtenbelt; Marco Tartaglia; Bruce D Gelb; Ihor R Lemischka
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

9.  Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene.

Authors:  Nara L M Sobreira; Elizabeth T Cirulli; Dimitrios Avramopoulos; Elizabeth Wohler; Gretchen L Oswald; Eric L Stevens; Dongliang Ge; Kevin V Shianna; Jason P Smith; Jessica M Maia; Curtis E Gumbs; Jonathan Pevsner; George Thomas; David Valle; Julie E Hoover-Fong; David B Goldstein
Journal:  PLoS Genet       Date:  2010-06-17       Impact factor: 5.917

10.  Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.

Authors:  Corina Anastasaki; Anne L Estep; Richard Marais; Katherine A Rauen; E Elizabeth Patton
Journal:  Hum Mol Genet       Date:  2009-04-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.